Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. (RGLS), sold 10,050 shares at $6.63 ($66K) on 2014-10-08, disclosed to the SEC on 2014-10-10.
Scheduled sale ($66k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.63 | 3,300 | $22K | 33.2% |
| 2 | $6.58 | 4,750 | $31K | 47.4% |
| 3 | $6.41 | 2,000 | $13K | 19.4% |
| Total | $6.56 avg | 10,050 | $66K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-03 | $69K | — | Filing → |